Biotechnology sector performed well on both public and private markets. Large public biotech stocks continued to climb while smaller stocks remained leveled. Private financing deal flow increased substantially, albeit leaving early stage start-ups behind. Biotech sector experienced an overall increase in VC activity during 2Q 2013 and after much less inspiring first quarter. The comeback of VC funding was consistent with strong public markets as well as high, 13, number of completed Life Sciences IPO transactions.
It is hard to underestimate the importance of technology in modern enterprises. From legacy manufacturing to artificial intelligence and life science breakthroughs, technology plays an ever-increasing role. However, the need to assign a specific value to it may arise only when the enterprise is faced with a strategic transition, such as a merger or an acquisition.